What's the hard cost of a pivotal drug trial? A lot less than you might expect
Of all the numbers cited by biopharma companies to defend drug costs, $2.6 billion — the estimated cost of bringing a prescription drug to market — is by far the most popular and resonant. But perhaps less well-known was the Tufts researchers’ estimate of the average cost of Phase III trials, the most expensive and arguably important component to scoring an OK: $255 million in 2014 dollars.
A new study is out to challenge that.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
